Industry Views On Quality-By-Design, Specifications To Be Presented At Cmte. Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
PhRMA, GPhA and USP will make presentations at Oct. 25-26 meeting of the Advisory Committee for Pharmaceutical Science. Question-based review for quality assessment will also be discussed.
You may also be interested in...
FDA Creates CMC Pilots To Put Quality Assessment Principles Into Practice
NDA and ANDA pilot programs will help transform the way CMC information is submitted and reviewed by FDA. Office of Generic Drugs' white paper on "question-based review" follows the introduction of an NDA pilot program in mid-July.
FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.
Bristol Sprycel For Gleevec-Resistant Leukemia To Get Committee Review At June ASCO Meeting
FDA’s Oncologic Drugs Advisory Committee will meet in Atlanta to review Bristol’s multi-targeted kinase inhibitor dasatinib for two leukemia indications.